+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
All Ages
All Genders
ID07131644

Randomized Trial Comparing Two Sirolimus Withdrawal Plans for Kaposiform Hemangioendothelioma

Led by West China Hospital · Updated on 2026-09-25

120

Participants Needed

1

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying kaposiform hemangioendothelioma KHE, a rare vascular tumor, to evaluate different strategies for stopping the drug sirolimus, which has shown effectiveness in treating KHE but often leads to tumor regrowth after stopping. This phase 2 randomized trial aims to find the best way to discontinue sirolimus to reduce rebound growth. The study is sponsored by West China Hospital and focuses on treatment methods. Participants receive sirolimus under two different plans one group gradually stops the drug over two months, while the other follows a schedule of taking sirolimus three days per week and resting four days per week for six months, then tapering off over two months. These strategies are compared to see which reduces tumor regrowth best. During the study, participants are monitored for tumor rebound over 12 months using clinical or imaging assessments. Researchers also track disease complications and any side effects throughout the year. Participants or their guardians provide informed consent, and their blood and liverkidney function are checked to ensure safety during treatment. The study runs from 2025 to 2028 and uses a single-blind design.

CONDITIONS

Brief Title

Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma

Research Team

Y

Yi Ji, PhD

J

Jiangyuan Zhou, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here